disk containing drug near the disk containing EDTA was observed for both isolates, which suggested the presence of MBLs.
PCR amplification of imp and vim genes was conducted by using primers based on conserved regions of the imp and vim genes (blaIMP-F: 5′-GAAG-G C G T T TAT G T T C ATA C T T-3 ′ , blaIMP-R: 5′-GTTTGCCTTACCAT ATTTGGA-3′, blaVIMG-F: 5′-GGT-GTTTGGTCGCATATC-3′, and bla VIMG-R 5′-TGGGCCATTCAGC CAGATC-3′) and heat-extracted DNA as template. Reactions were performed in a T-gradient instrument (Biometra, Göttingen, Germany) with the following reaction conditions: 1 cycle at 95°C for 5 min, 52°C for 15 min, and 72°C for 6 min, followed by 30 cycles at 95°C for 1 min, 52°C for 1 min, and 72°C for 1 min, and a final reaction at 72°C for 20 min. Amplified fragments were sequenced on both strands by using an ABI Prism DNA 3700 (Applied Biosystems, Foster City, CA, USA), and nucleotide sequences were compared by using BLAST (National Center for Biotechnology Information, Bethesda, MD, USA, www.ncbi.nlm.nih.gov/ Tools/). Nucleotide sequences were completely homologous to the vim-2 coding gene.
Two repetitive-element-based PCR (rep-PCR) assays (ERIC-PCR and REP-PCR) with primers REP-1 (5′-IGCGCCGICATCAGGC-3′), REP-2 (5′-CGTCTTATCAGGCC-TAC-3′), ERIC-1 (5′-CACTTAGGG GTCCTCAATGTA-3′), and ERIC-2 (5′-AAGTAAGTGACTGGGGT-GAGCG-3′) were used to characterize isolates. PCR conditions were 94°C for 2 min, 30 cycles at 94°C for 30 s, 50°C for 1 min, and 72°C for 4 min, and a final reaction at 72°C for 7 min. Banding patterns were visually analyzed after electrophoresis of samples. Variations in band intensity were not considered to indicate genetic differences. Banding patterns obtained by REP-PCR and ERIC-PCR assays were identical in both isolates (data not shown).
Among the MBLs acquired by P. putida, IMP-1 was reported by Senda et al. in Japan in 1996 (1) and later reported in Taiwan and Japan (2). IMP-12 was the first IMP MBL described in P. putida in Europe (3). VIM-1 in P. putida was first reported in Europe (4), and VIM-2 in P. putida was first reported in Taiwan, Republic of Korea, Japan, and France (5,6). Our isolates were resistant to aztreonam (MIC 64 µg/mL). However, carbapenem-susceptible P. putida had low levels of susceptibility because the MIC 50 was only 1 dilution below the current breakpoint (7, 8) . Aztreonam resistance could not be transferred by conjugation between IMP-1-producing (aztreonam-resistant) P. putida and P. aeruginosa (2) and is not associated with a transposon carrying blaVIM-2 (6) . No evidence of extended-spectrum β-lactamases was detected in our isolates by classic synergy assays with clavulanate plus aztreonam, ceftazidime, or cefotaxime. VIM-6-producing P. putida isolates from Singapore (9) were more resistant to aztreonam (MIC >128 µg/mL), ceftazidime, and cefepime (MIC >256 µg/mL).
Detection of bla VIM-2 in Pseudomonas in South America was initially reported by the SENTRY Antimicrobial Surveillance Program (10) and included 1 P. fluorescens isolate in Chile and 3 P. aeruginosa isolates in Venezuela. To the best of our knowledge, our report is the first of VIM-2 in P. putida in Latin America. VIM-2-producing P. putida, which were originally restricted to East Asia and only very recently found in France, may represent an emerging pathogen or function as reservoirs for resistance because of their widespread presence in the hospital environment.
Multidrug-resistant Acinetobacter baumannii, Russia
To the Editor: During the past decade, nosocomial infections due to multidrug-resistant Acinetobacter baumannii have been described with increasing frequency, mostly in intensive care units (ICUs), resulting in therapeutic difficulties (1) . The main mechanism for resistance to extended-spectrum cephalosporins in A. baumannii is attributed to the overexpression of chromosome-encoded cephalosporinases or to plasmidencoded Ambler class A, B, and D β-lactamases (2) . A. baumannii that produce PER-1 extended-spectrum β-lactamase (ESBL) are rarely isolated outside Turkey and remain susceptible to carbapenems (3). Here we describe what we believe is the first ESBL-producing A. baumannii isolate resistant to carbapenems and the first characterization of a PER-1 A. baumannii isolate from Russia, further supporting the emergence and dissemination of PER-1 A. baumannii strains in eastern Europe and outside Turkey (3, 4) .
On April 17, 2005, a 79-year-oldman was hospitalized in the cardiology ward of a private hospital in Moscow, Russia, with cardiac arrhythmia and a pulmonary infarction subsequent to a pulmonary embolism. After 1 week, he was transferred to the ICU for multiple organ failure related to a nosocomial infection caused by an A. baumannii strain
